Durvalumab Approved for Endometrial Cancer

  Published 1 year ago

Durvalumab combo treats advanced endometrial cancer; AstraZeneca leads oncology innovation.

  • Durvalumab plus chemo for first-line advanced/recurrent pMMR endometrial cancer.
  • Maintenance therapy combines Durvalumab and olaparib post-chemotherapy.
  • AstraZeneca focuses on oncology, cardiovascular, renal, and rare diseases.

You might like these

Ola Electric Ferrite Motor Certified

India Tightens FDI Rules for Foreign, Owned Firms

Enviro Infra Engineers Expands Renewable & EPC Projects

India Markets Dip on Middle East Tensions, Crude Rises

TPREL Surpasses 3.4 GW Rooftop Solar Milestone

Mahanagar Gas Outperforms Peers Amid Bullish Outlook

ITD Cementation Q1 Profit Rises 21%

News that matters the most ⚡